Getting the dose of vancomycin right in the neonate

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 4, 2011, Pages 247-249

  Van Den Anker, John N ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

AREA UNDER THE CURVE; DOSE KIDNEY FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MONITORING; EDITORIAL; HUMAN; LOADING DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NEWBORN; NEWBORN CARE; OTOTOXICITY; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; DRUG MONITORING; HUMANS; INFANT, NEWBORN; VANCOMYCIN;

EID: 79955978885     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP49247     Document Type: Editorial

References (14)

1. Couto RC, Carvalho AA, Pedrosa TM, Pedroso ER, Neto MC, Biscione FM.A10-year prospective surveillance of nosocomial infections in neonatal intensive care units. Am J Infect Control. 2007; 35: 183-189. (Pubitemid 46551326)
2. Rybak MJ, Lomaestro BM, Rotschafer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Disease Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009; 49: 325-327.
3. Dehority W. Use of vancomycin in pediatrics. Pediatr Infect Dis J. 2010; 29: 462-464.
4. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern of death by character assassination? Am J Med. 2010; 123: 182.e1-182.e7.
5. Lodise TP, Lomaestro B, Graves J, Drusano GL. Large vancomycin doses (at least four grams a day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008; 52: 1330-1336. (Pubitemid 351521995)
6. Young TE, Magnum B. Neofax®, 20th Edition. Thomson Healthcare; 2007.
7. Badran EF, Shamayleh A, Irshaid YM. Pharmacokinetics of vancomycin in neonates admitted to the neonatology unit at the Jordan university hospital. Int J Clin Pharmacol Ther. 2011; 49: 252-257.
8. Tan WH, Brown N, Kelsall AW, McClure RJ. Dose regimen for vancomycin not needing serum peak levels? Arch Dis Child Fetal Neonatal Ed. 2002; 87: 214-246.
9. De Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. Vancomycin population pharmacokinetics in neonates. Clin Pharmacol Ther. 2000; 67: 360-367.
10. Grimsley C, Thomson AH. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch Dis Child Fetal Neonatal Ed. 1999; 81: 221-227.
11. Saunders N. Why monitor peak vancomycin concentrations? Lancet 1994; 344: 1748-1750.
12. De Hoog M, Mouton JW, van den Anker J. Why monitor peak vancomycin concentrations. Lancet 1995; 345: 646.
13. Lo Y-L, van Hasselt JG, Heng S-C, Lim C-T, Lee T-C, Charles BG. Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination. Antimicrob Agents Chemother. 2010; 54: 2626-2632.
14. Marques-Minana M-R, Saadeddin A, Peris J-E. Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline. Br J Clin Pharmacol. 2010; 70: 713-720.